- The FDA has approved Eton Pharmaceuticals Inc's (NASDAQ:ETON) Rezipres (ephedrine hydrochloride injection) to treat clinically significant hypotension occurring in the setting of anesthesia.
- Rezipres is already available in Europe.
- The company currently owns or receives royalties from four FDA-approved products, including Alkindi Sprinkle, Biorphen, Rezipres, and Alaway Preservative Free, and has five additional products that have been submitted to the FDA.
- Price Action: ETON shares are up 7.06% at $6.98 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
